Prodotto aggiunto correttamente al carrello.

discount label
H-RIQRGPGRAFVTIGK-OH
Visualizzare in 3D

Biosynth logo

H-RIQRGPGRAFVTIGK-OH

Rif. 3D-PP47151

1mg
310,00 €
10mg
348,00 €
100mg
631,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-RIQRGPGRAFVTIGK-OH
Descrizione:

Peptide H-RIQRGPGRAFVTIGK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-RIQRGPGRAFVTIGK-OH include the following: An endogenous HIV envelope-derived peptide without the terminal NH3+ group anchor is physiologically presented by major histocompatibility complex class I Y Samino, D Lopez , S Guil, P de Leon - Journal of Biological , 2004 - ASBMBhttps://www.jbc.org/article/S0021-9258(18)52725-3/abstract Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific Y Nakagawa, T Takeshita, JA Berzofsky - , 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2567.2000.00092.x Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution Y Nakagawa, H Kikuchi, H Takahashi - Biophysical journal, 2007 - cell.comhttps://www.cell.com/biophysj/pdf/S0006-3495(07)71061-5.pdf Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue X Huang, M Charles Smith, JA Berzofsky - FEBS , 1996 - Wiley Online Libraryhttps://febs.onlinelibrary.wiley.com/doi/abs/10.1016/0014-5793(96)00912-X Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules T Takeshita, S Kozlowski , RD England - International , 1993 - academic.oup.comhttps://academic.oup.com/intimm/article-abstract/5/9/1129/708906 Use of Helper T Cell-Inducing Peptides from Conserved Regions in HIV-1 env in a Noncovalent Mixture with a CTL-Inducing V3-Loop Peptide for in Vivo Induction of PN NEHETE, RB ARLINGHAUS, KJ SASTRY - Viral immunology, 1994 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/vim.1994.7.189 Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1 JPM Langedijk , NKT Back, E Kinney-Thomas - Archives of , 1992 - Springerhttps://link.springer.com/article/10.1007/BF01309690 Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence JD Ahlers, T Takeshita - Proceedings of the , 1997 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.94.20.10856 Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells H Takahashi, Y Nakagawa, K Yokomuro - International , 1993 - academic.oup.comhttps://academic.oup.com/intimm/article-abstract/5/8/849/653193 Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human H Takahashi, R Houghten, SD Putney - The Journal of , 1989 - rupress.orghttps://rupress.org/jem/article-abstract/170/6/2023/50194 NMR study of a peptide derived from the principal neutralization domain of HIV-1 and its conjugates with bovine pancreatic trypsin inhibitor G Wu - 1997 - search.proquest.comhttps://search.proquest.com/openview/1dbad4b41e1c9fef42522c8b6cb6bf5b/1?pq-origsite=gscholar&cbl=18750&diss=y Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with CE Gomez , D Rodrı́guez , JR Rodrı́guez, F Abaitua - Vaccine, 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X01003899 Solid-phase peptide synthesis, lead generation, and optimization B Seligmann, M Lebl, KS Lam - Chemistry and Molecular Diversity in Drug , 1998 - 5z.comhttp://www.5z.com/mlebl/publications/1998CombChemMolDivDrugDisc.pdf

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP47151 H-RIQRGPGRAFVTIGK-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".